New findings about the role of senescence in tumor biology are critically reviewed with respect to new suggestions for cancer therapy leveraging genetic and pharmacological methods to prevent senescence or to selectively kill senescent cells in tumors. and drives normal organismic aging and (ii) induction of senescence was positively selected for in evolution for several reasons, among them to protect cells and organisms from cancer. a double-edged sword in cancer Flunisolide development. In current cancer therapy, cellular senescence is, on the one hand, intended to occur in tumor cells, as thereby the therapeutic outcome is improved, but might, on the other hand, also be induced unintentionally in non-tumor cells, causing inflammation, secondary tumors, and cancer relapse. Importantly, organismic aging leads to accumulation of senescent cells in tissues and organs of aged individuals. Senescent cells can occur transiently, e.g., Flunisolide during embryogenesis or during wound healing, with beneficial effects on tissue homeostasis and regeneration or accumulate chronically in tissues, which detrimentally affects the microenvironment by de- or transdifferentiation of senescent cells and their neighboring stromal cells, loss of tissue specific functionality, and induction of the senescence-associated secretory phenotype, an increased secretory profile consisting of pro-inflammatory and tissue remodeling factors. These factors shape their surroundings toward a pro-carcinogenic microenvironment, which fuels the development of aging-associated cancers together with the accumulation of mutations over time. We are presenting an overview of well-documented stress situations and signals, which induce senescence. Among them, oncogene-induced senescence and stress-induced premature senescence are prominent. New findings about the role of senescence in tumor biology are critically reviewed with respect to new suggestions for cancer therapy leveraging genetic and pharmacological methods to prevent senescence or to selectively kill senescent cells in tumors. and drives normal organismic aging and (ii) induction of senescence was positively selected for in evolution for several reasons, among them to protect cells and organisms from cancer. Both of these ideas were highly speculative, but over the last 20?years were shown to be correct in part (2, 4C8). On the other hand, reports that establish a beneficial and important role of cellular senescence in embryogenesis (9, 10) and wound healing (11) imply that senescence might have evolved for other reasons as well. The basic arguments about the role of senescence in cancer protection are as follows: senescent cells have lost the ability to undergo cell division permanently, although they may be metabolically fully active. This would certainly protect individuals carrying a primary cancer from further cancerous growth. However, this has to be seen in a different way nowadays as compared to the time when this anticancer hypothesis was first published (8), as knowledge of the genetics of cancer and senescence increased rapidly over the last few years. By this, we mean on the one hand the sequence of mutational events that takes place in growing tumors (12, 13), and on the other hand the knowledge of biochemical senescence markers in senescent cells (6, 14C17). Most importantly, senescent cells may be prone to genetic and epigenetic instability (18, 19), which is also a hallmark of cancer cells (12). In addition, the senescence-associated secretory phenotype (SASP) directly causes transformation of neighboring cells and destruction of the extracellular matrix, other hallmarks of cancer growth, which help to spread malignant cells in the body (2, 20, 21). Thus, cellular senescence can be viewed as a typical example for antagonistic pleiotropy: at young age, senescence might protect cells from transformation into primary tumors; however, at old age senescent cells generate a pro-tumorigenic microenvironment. In this review, we will summarize mechanisms of senescence induction, especially in the context of aging-associated cancers and tumor therapy. While cellular senescence was originally believed to be caused by telomere shortening alone, increasing evidence suggested additional inducers of senescence. These inducers of senescence include the activation of DNA damage response pathways by cytotoxic compounds or ROS as well as activation of oncogenes. The contribution of senescent cells to a pro-oncogenic microenvironment will become likened and talked about TZFP to additional cancer-associated cells, such as for example CAF. Finally, we will bring in current and long term therapy choices focusing on tumor-, non-senescent-, and senescent cells and discuss their potential impact on cell destiny decisions inside the tumor stroma. Systems of Flunisolide Cellular Senescence Induction and Their Reference to Tumor Biology Biomarkers of Cellular Senescence For a long period, since the finding of replicative senescence in cell tradition (3) until fairly lately [summarized in Ref. (22)], it had been not yet determined if replicative senescence can be (i) an artifact of cell tradition, due to unphysiological oxygen Flunisolide partial pressure perhaps;.